Clinical trial
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in…
NCT00121680 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00121680 |
|---|---|
| Title | A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma |
| Official title | A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma |
| Lead sponsor | Eisai Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Metastatic Melanoma |
| Intervention type | Drug |
| Interventions | E7080 |
| Enrollment | 115 |
| Start date | Jul 1, 2005 |
| Primary completion | Sep 1, 2011 |
| Completion | May 1, 2015 |
| First posted | Jul 21, 2005 |
| Last update posted | Dec 11, 2015 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: